COMPARISON
Cagrilintide vs Semaglutide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Cagrilintide is authorised or registered in 0 and Semaglutide in 10 of the 10 registers read. Cagrilintide: highest phase Phase 3 (17 phase 3 trials, 0 with posted results). Semaglutide: highest phase Phase 4 (after approval). 51 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Registered trials differs | 66 clinicaltrials.gov · 2026-10-03 | 861 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | Not checked no record of "fdaLabel" for cagrilintide | FDA-approved: OZEMPIC openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for cagrilintide | 2018-02-08 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for cagrilintide | A10BJ06 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Cagrilintide | placebo | Semaglutide | placebo |
|---|---|---|---|---|
| Nausea | 29.0% | 14.8% | 19.5% | 4.5% |
| COVID-19 | 16.1% | 13.1% | 17.0% | 17.8% |
| Constipation | 16.1% | 13.1% | 8.9% | 2.8% |
| Diarrhoea | 16.1% | 6.6% | 11.8% | 4.5% |
| Vomiting | 9.7% | 1.6% | 8.6% | 1.6% |
| Fatigue | 9.7% | 1.6% | - | - |
| Gastrooesophageal reflux disease | 9.7% | 1.6% | - | - |
| Back pain | 6.5% | 3.3% | - | - |
| Eructation | 6.5% | 0.0% | - | - |
| Gastroenteritis | 6.5% | 6.6% | - | - |
| Nasopharyngitis | - | - | 7.5% | 6.1% |
| Decreased appetite | - | - | 6.3% | 1.3% |
| Dyspepsia | - | - | 5.3% | 1.2% |
| Headache | - | - | 4.0% | 2.1% |
| Upper respiratory tract infection | - | - | 2.7% | 1.9% |
Trial register Cagrilintide: 1 placebo-controlled trials; Semaglutide: 50. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Cagrilintide side effects · Semaglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Cagrilintide | Semaglutide | Register |
|---|---|---|---|
| United States | Not on the register | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Not on the register | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
51 registered trials include both
| NCT05567796 | A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight ACTIVE_NOT_RECRUITING · updated 2026-09-30 |
|---|---|
| NCT06323174 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise COMPLETED · updated 2026-09-30 |
| NCT07011667 | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term ACTIVE_NOT_RECRUITING · updated 2026-09-30 |
| NCT07253285 | A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight RECRUITING · updated 2026-09-30 |
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Los RECRUITING · updated 2026-09-30 |
| NCT06131372 | A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema COMPLETED · updated 2026-09-24 |
| NCT06797869 | A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy COMPLETED · updated 2026-09-10 |
| NCT07010432 | The Role of the Amylin Analogue Cagrilintide in Bone Metabolism RECRUITING · updated 2026-09-10 |
| NCT07184086 | A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet ACTIVE_NOT_RECRUITING · updated 2026-09-10 |
| NCT06323161 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal I COMPLETED · updated 2026-09-09 |
| NCT06534411 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGL COMPLETED · updated 2026-09-09 |
| NCT07282613 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes RECRUITING · updated 2026-09-09 |
| 2023-506924-94-00 | The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in par Not stated · updated 2026-09-08 |
| 2023-509176-42-00 | Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy
and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for wei Not stated · updated 2026-09-08 |
| NCT06221969 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With COMPLETED · updated 2026-09-04 |
| NCT07745504 | A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight RECRUITING · updated 2026-09-04 |
| NCT05669755 | REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels ACTIVE_NOT_RECRUITING · updated 2026-08-31 |
| NCT06716307 | A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overwei COMPLETED · updated 2026-08-31 |
| 2025-522488-14-00 | A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes Not stated · updated 2026-08-04 |
| 2023-509600-15-00 | Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in parti Not stated · updated 2026-08-03 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.